A Phase 1 and Biodistribution Study of ABT-806i, an
EGFR
EGFRvIII
SPECT imaging
biodistribution
solid tumors
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
08
07
2020
accepted:
16
09
2020
pubmed:
30
1
2021
medline:
27
8
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of
Identifiants
pubmed: 33509972
pii: jnumed.120.253146
doi: 10.2967/jnumed.120.253146
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunoconjugates
0
Indium Radioisotopes
0
Indium-111
E9NGC49E0T
ErbB Receptors
EC 2.7.10.1
depatuxizumab
W984C353CG
Banques de données
ClinicalTrials.gov
['NCT01472003']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-794Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.